Literature DB >> 21500872

Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.

B Ryan Phelps1, Natella Rakhmanina.   

Abstract

Antiretroviral (ARV) therapy has been shown to achieve high therapeutic efficacy in treating pediatric HIV disease. The delivery of affordable, child friendly, and easy to store and administer ARV drugs is key to the successful management of HIV in children. In recent years, significant progress has been made in scaling up the access to pediatric ARV therapy among children worldwide. Despite the improved ARV drug access, multiple challenges remain concerning palatability and efficient delivery of ARV drugs to children from infancy into adolescence. Data are limited regarding developmental changes in pharmacokinetics of individual ARV drugs, and pediatric and adult fixed-dose combinations. This review provides a practical discussion regarding the pharmacokinetics of ARV agents in pediatric HIV-infected patients, as well as the practical challenges of currently available formulations, such as palatability of liquid formulations, challenges of crushing tablets, and using adult and pediatric fixed-dose combinations.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21500872     DOI： 10.2165/11587300-000000000-00000

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN： 1174-5878            Impact factor:   3.022


  114 in total

1.  Weight variability of pharmacist-dispensed split tablets.

Authors:  Jack M Rosenberg; Joseph P Nathan; Fotios Plakogiannis
Journal:  J Am Pharm Assoc (Wash)       Date:  2002 Mar-Apr

2.  Emerging antiretroviral drug interactions.

Authors:  Paul A Pham; Charles Flexner
Journal:  J Antimicrob Chemother       Date:  2010-12-05       Impact factor: 5.790

3.  Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling.

Authors:  H Vermeiren; E Van Craenenbroeck; P Alen; L Bacheler; G Picchio; P Lecocq
Journal:  J Virol Methods       Date:  2007-06-15       Impact factor: 2.014

4.  Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients.

Authors:  J P Dieleman; I C Gyssens; M E van der Ende; S de Marie; D M Burger
Journal:  AIDS       Date:  1999-03-11       Impact factor: 4.177

5.  Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin/clavulanate potassium, cefprozil and azithromycin in pediatric patients.

Authors:  J L Powers; W M Gooch; L P Oddo
Journal:  Pediatr Infect Dis J       Date:  2000-12       Impact factor: 2.129

6.  Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.

Authors:  Henriëtte J Scherpbier; Vincent Bekker; Dasja Pajkrt; Suzanne Jurriaans; Joep M A Lange; Taco W Kuijpers
Journal:  Pediatrics       Date:  2007-02-16       Impact factor: 7.124

7.  Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus.

Authors:  Julia B Purdy; Rachel I Gafni; James C Reynolds; Steven Zeichner; Rohan Hazra
Journal:  J Pediatr       Date:  2008-04       Impact factor: 4.406

8.  Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infection.

Authors:  B U Mueller; K M Butler; V L Stocker; F M Balis; P Brouwers; P Jarosinski; R N Husson; L L Lewis; D Venzon; P A Pizzo
Journal:  Pediatrics       Date:  1994-11       Impact factor: 7.124

9.  Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.

Authors:  Rohan Hazra; Frank M Balis; Antonella N Tullio; Ellen DeCarlo; Carol J Worrell; Seth M Steinberg; John F Flaherty; Kitty Yale; Marianne Poblenz; Brian P Kearney; Lijie Zhong; Dion F Coakley; Stephane Blanche; Jean Louis Bresson; Judith A Zuckerman; Steven L Zeichner
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial.

Authors:  C V Fletcher; R C Brundage; T Fenton; C G Alvero; C Powell; L M Mofenson; S A Spector
Journal:  Clin Pharmacol Ther       Date:  2007-07-04       Impact factor: 6.875
View more
  9 in total

1.  Nevirapine Resistance in Previously Nevirapine-Unexposed HIV-1-Infected Kenyan Infants Initiating Early Antiretroviral Therapy.

Authors:  Bhavna H Chohan; Kenneth Tapia; Sarah Benki-Nugent; Brian Khasimwa; Musa Ngayo; Elizabeth Maleche-Obimbo; Dalton Wamalwa; Julie Overbaugh; Grace John-Stewart
Journal:  AIDS Res Hum Retroviruses       Date:  2015-04-22       Impact factor: 2.205

2.  Challenges and Opportunities in the Development of HIV Medications in Pediatric Patients.

Authors:  Gueorgui Dubrocq; Natella Rakhmanina; B Ryan Phelps
Journal:  Paediatr Drugs       Date:  2017-04       Impact factor: 3.022

3.  Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.

Authors:  Brookie M Best; Edmund V Capparelli; Huy Diep; Steven S Rossi; Michael J Farrell; Elaine Williams; Grace Lee; John N van den Anker; Natella Rakhmanina
Journal:  J Acquir Immune Defic Syndr       Date:  2011-12-01       Impact factor: 3.731

Review 4.  Pharmacotherapy of pediatric HIV infection.

Authors:  Natella Rakhmanina; B Ryan Phelps
Journal:  Pediatr Clin North Am       Date:  2012-08-22       Impact factor: 3.278

Review 5.  The Need for Pediatric Formulations to Treat Children with HIV.

Authors:  Adrienne F Schlatter; Andrew R Deathe; Rachel C Vreeman
Journal:  AIDS Res Treat       Date:  2016-06-16

6.  Understanding acceptance of and adherence to a new formulation of paediatric antiretroviral treatment in the form of pellets (LPV/r)-A realist evaluation.

Authors:  Ariadna Nebot Giralt; Christiana Nöstlinger; Janice Lee; Olawale Salami; Marc Lallemant; Washington Onyango-Ouma; Isaac Nyamongo; Bruno Marchal
Journal:  PLoS One       Date:  2019-08-21       Impact factor: 3.240

7.  Estimating age-based antiretroviral therapy costs for HIV-infected children in resource-limited settings based on World Health Organization weight-based dosing recommendations.

Authors:  Kathleen Doherty; Shaffiq Essajee; Martina Penazzato; Charles Holmes; Stephen Resch; Andrea Ciaranello
Journal:  BMC Health Serv Res       Date:  2014-05-02       Impact factor: 2.655

8.  Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study.

Authors:  Lola Falcon-Neyra; Claudia Palladino; María Luisa Navarro Gómez; Pere Soler-Palacín; María Isabel González-Tomé; Santiago J De Ory; Marie Antoinette Frick; Clàudia Fortuny; Antoni Noguera-Julian; Elena Bermúdez Moreno; Juan Luis Santos; Peter Olbrich; Luis F López-Cortés; Verónica Briz; Olaf Neth
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

9.  Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV.

Authors:  Deborah Ford; Rebecca Turner; Anna Turkova; Martina Penazzato; Victor Musiime; Mutsa Bwakura-Dangarembizi; Avy Violari; Chishala Chabala; Thanyawee Puthanakit; Tavitiya Sudjaritruk; Tim R Cressey; Marc Lallemant; Diana M Gibb
Journal:  J Acquir Immune Defic Syndr       Date:  2018-08-15       Impact factor: 3.731
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.